PMID- 17300723
OWN - NLM
STAT- MEDLINE
DCOM- 20070313
LR  - 20181201
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 4
DP  - 2007 Feb 14
TI  - Genetic distance and heterogenecity between quasispecies is a critical predictor 
      to IFN response in Egyptian patients with HCV genotype-4.
PG  - 16
AB  - BACKGROUND: HCV is one of the major health problems in Egypt, where it is highly 
      prevalent. Genotype 4 is the most common genotype of HCV and its response to 
      treatment is still a controversy. METHODS: HCV genotype 4 quasispecies diversity 
      within the 5' untranslated region (5'UTR) was studied in a series of 22 native 
      Egyptian patients with chronic hepatitis C virus with no previous treatment who 
      satisfied all NIH criteria for combined treatment of pegylated IFN and ribavirine 
      and was correlated with the outcome of treatment. The study also included 7 
      control patients with no antiviral treatment. HCV sequencing was done using the 
      TRUGENE HCV 5-NC genotyping kit. RESULTS: At the 48th week of treatment, 15 
      patients (68%) showed virological response. Whereas HCV-RNA was still detected in 
      7 patients (32%) in this period; of those, 6 experienced a partial virological 
      response followed by viral breakthrough during treatment. Only one patient did 
      not show any virological or chemical response. The four females included in this 
      study were all responders. There was a significant correlation between the 
      response rate and lower fibrosis (p = 0.026) as well as the total number of 
      mutation spots (including all the insertions, deletions, transitions and 
      transversions) (p = 0.007, p = 0.035). CONCLUSION: Patients who responded to 
      interferon treatment had statistically significant less number in both 
      transitions (p = 0.007) and the genetic distances between the quasispecies (p = 
      0.035). So, viral genetic complexity and variability may play a role in the 
      response to IFN treatment. The consensus alignment of all three groups revealed 
      no characteristic pattern among the three groups. However, the G to A transitions 
      at 160 was observed among non responders who need further study to confirm this 
      observation.
FAU - Zekri, Abdel Rahman N
AU  - Zekri AR
AD  - Virology and Immunology Unit, Cancer Biology Department, National Cancer 
      Institute, Cairo University, Cairo, Egypt. ncizekri@yahoo.com
FAU - El-Din, Hanaa M Alam
AU  - El-Din HM
FAU - Bahnassy, Abeer A
AU  - Bahnassy AA
FAU - Khaled, Mohsen M
AU  - Khaled MM
FAU - Omar, Ashraf
AU  - Omar A
FAU - Fouad, Inas
AU  - Fouad I
FAU - El-Hefnewi, Mahmoud
AU  - El-Hefnewi M
FAU - Thakeb, Fouad
AU  - Thakeb F
FAU - El-Awady, Mostafa
AU  - El-Awady M
LA  - eng
SI  - GENBANK/AY661552
SI  - GENBANK/AY673080
SI  - GENBANK/AY673081
SI  - GENBANK/AY673082
SI  - GENBANK/AY673083
SI  - GENBANK/AY673084
SI  - GENBANK/AY673085
SI  - GENBANK/AY673086
SI  - GENBANK/AY673087
SI  - GENBANK/AY673088
SI  - GENBANK/AY673089
SI  - GENBANK/AY673090
SI  - GENBANK/AY673091
SI  - GENBANK/AY673092
SI  - GENBANK/AY673093
SI  - GENBANK/AY673094
SI  - GENBANK/AY673095
SI  - GENBANK/AY673096
SI  - GENBANK/AY673097
SI  - GENBANK/AY673098
SI  - GENBANK/AY673099
SI  - GENBANK/AY673100
SI  - GENBANK/AY673101
SI  - GENBANK/AY673102
SI  - GENBANK/AY673103
SI  - GENBANK/AY673104
SI  - GENBANK/AY673105
SI  - GENBANK/AY673106
SI  - GENBANK/AY673107
SI  - GENBANK/AY673108
SI  - GENBANK/AY673109
SI  - GENBANK/AY673110
SI  - GENBANK/AY673111
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070214
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (5' Untranslated Regions)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
SB  - IM
MH  - 5' Untranslated Regions/genetics
MH  - Adolescent
MH  - Adult
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - Egypt
MH  - Female
MH  - Genetic Heterogeneity
MH  - Hepacivirus/classification/*drug effects/genetics/isolation & purification
MH  - Hepatitis C, Chronic/*drug therapy/*virology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Mutation/genetics
MH  - Phylogeny
MH  - Polyethylene Glycols
MH  - *Polymorphism, Genetic
MH  - RNA, Viral/genetics
MH  - Recombinant Proteins
MH  - Ribavirin/administration & dosage/*therapeutic use
MH  - Sequence Analysis, DNA
MH  - Statistics as Topic
MH  - Treatment Outcome
PMC - PMC1805740
EDAT- 2007/02/16 09:00
MHDA- 2007/03/14 09:00
PMCR- 2007/02/14
CRDT- 2007/02/16 09:00
PHST- 2006/12/17 00:00 [received]
PHST- 2007/02/14 00:00 [accepted]
PHST- 2007/02/16 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2007/02/16 09:00 [entrez]
PHST- 2007/02/14 00:00 [pmc-release]
AID - 1743-422X-4-16 [pii]
AID - 10.1186/1743-422X-4-16 [doi]
PST - epublish
SO  - Virol J. 2007 Feb 14;4:16. doi: 10.1186/1743-422X-4-16.